Copyright
©The Author(s) 2025.
World J Cardiol. Dec 26, 2025; 17(12): 113820
Published online Dec 26, 2025. doi: 10.4330/wjc.v17.i12.113820
Published online Dec 26, 2025. doi: 10.4330/wjc.v17.i12.113820
Table 1 Table showing the characteristics of the studies included in the meta-analysis
| Number | Trial name | Type of study | Follow up duration | Left ventricular mass | Final heart rate | Intervention group (n) |
| 1 | Dos Santos et al[10], 2021 | Prospective, randomized, open-label, single-center clinical trial | Minimum 1 year, maximum 3 years | IG: 174.2 ± 60.8 g, CG: 148.2 ± 52.9 g | IG: 74.6 ± 6.5 bpm, CG: 98.2 ± 6.5 bpm (at 36 months) | 16 |
| 2 | Rivinius et al[12], 2022 | Observational cohort | 5 years | IG: 154.8 ± 23.4 g, CG: 177.3 ± 28.4 g | IG: 73.3 ± 9.1, CG: 80.4 ± 10.1 | 50 |
| 3 | Rivinius et al[11], 2018 | Observational retrospective single-center study | 2 years | Ivabradine: 151.3 ± 39.8 g, metoprolol: 178.3 ± 54.8 g | IG: 76.7 ± 10.2 bpm; CG: 82.0 ± 10.0 bpm | 40 |
| 4 | Doesch et al[13], 2007 | Open-label, prospective, non-randomized crossover trial | 8 weeks | NA | NA | NA |
- Citation: Ahmed F, Ali R, Haider F, Shah HH, Farhan K, Jahangir K, Kiyani M, Khan MS, Afzaal Z, Khan SI, Nizam MA, Usman M, Gohar N, Ahmed M, Mirza TR, Sattar Y, Taha A, Almendral J, Alenezi F. Efficacy of ivabradine in heart rate reduction after cardiac transplantation: Systematic review and meta-analysis. World J Cardiol 2025; 17(12): 113820
- URL: https://www.wjgnet.com/1949-8462/full/v17/i12/113820.htm
- DOI: https://dx.doi.org/10.4330/wjc.v17.i12.113820